Redefining Every Stage of Investment (RESI) Seed to Exit Conference Redefining Every Stage of Investment (RESI) Seed to Exit Certara2025 年 9 月 5 日
The Pharmacometrics Africa Conference 2025 (PMXAC-2025) Conference The Pharmacometrics Africa Conference 2025 (PMXAC-2025) Certara2025 年 9 月 4 日
Certara Biotech Forum: Workshop on Developing Investor-Ready Strategies Live Events Certara Biotech Forum: Workshop on Developing Investor-Ready Strategies Certara2025 年 9 月 4 日
The Pursuit of Certainty: Integrated Evidence and the evolving drug development and reimbursement landscape Webinar The Pursuit of Certainty: Integrated Evidence and the evolving drug development and reimbursement landscape Certara2025 年 9 月 3 日
Designing a High-Value Drug Development Program: From Concept to First-in-Human (FIH) Webinar 设计高价值药物研发计划:From Concept to First-in-Human (FIH) Danielle Pillsbury2025 年 8 月 29 日
Blueprint for Biotech Success: De-risking Early Development to Secure Long-Term Value Webinar Blueprint for Biotech Success: De-risking Early Development to Secure Long-Term Value Certara2025 年 8 月 21 日
ToxStudio®: In silico tools to accelerate toxicology assessments Webinar ToxStudio®: In silico tools to accelerate toxicology assessments Certara2025 年 8 月 19 日
Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma Publication Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma Explore comprehensive population pharmacokinetic analyses of belantamab mafodotin, evaluating both monotherapy and combination regimens in…Certara2025 年 8 月 13 日
Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2− Metastatic Breast Cancer Data From the Phase 3 TROPiCS‐02 Trial Publication Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2− Metastatic Breast Cancer Data From the Phase 3 TROPiCS‐02 Trial Explore updated results from the Phase 3 TROPiCS-02 trial of Sacituzumab Govitecan in advanced HR+/HER2–…Certara2025 年 8 月 13 日